Towa Pharmaceutical Co. Ltd. Reports Consolidated and Non Consolidated Earnings Results for the Year Ended March 2012; Revised Earnings Guidance for the Year Ending March 2013
May 13, 2012
Share
Towa Pharmaceutical Co. Ltd. reported consolidated and non consolidated earnings results for the year ended March 2012. For the year, the company reported net sales of JPY 48,719 million from JPY 46,145 million reported a year ago. Operating income was JPY 9,107 million from JPY 9,654 million reported a year ago. Net income was JPY 5,737 million from JPY 5,846 million reported a year ago. Net profit before tax was JPY 9,733 million from JPY 9,435 million reported a year ago. Net cash provided by operating activities was JPY 3,379 million from JPY 5,739 million reported a year ago. Capital expenditure was JPY 11.2 billion.
For the year, on non consolidated basis, the company reported net sales of JPY 47,225 million from JPY 44,780 million reported a year ago. Operating income was JPY 9,025 million from JPY 9,386 million reported a year ago. Net income was JPY 5,696 million from JPY 5,683 million reported a year ago.
For the year ending March 2013, the company revised net sales of JPY 54,400 million, operating income of JPY 8,300 million, net income of JPY 5,100 million from previous expectations of net sales of JPY 52,200 million, operating income of JPY 6,300 million, net income of JPY 3,800 million. The company expects capital expenditure of JPY 12.5 billion.
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
Towa Pharmaceutical Co. Ltd. Reports Consolidated and Non Consolidated Earnings Results for the Year Ended March 2012; Revised Earnings Guidance for the Year Ending March 2013